The Development of UM-203, A Reversible Covalent STING Antagonist

The cGAS-STING pathway is a critical component of the innate immune system, responsible for detecting cytosolic DNA and triggering inflammatory signaling. While essential for host defense, aberrant activation of this pathway is linked to a range of inflammatory and autoimmune disorders. Consequently, STING has emerged as a compelling therapeutic target. Herein we report the development of the first reversible covalent STING inhibitor, i.e., <b>UM-203</b> which employs an alkyne-thiazole warhead. <b>UM-203</b> inhibits STING-dependent signaling in both mouse and human systems. Notably, <b>UM-203</b> maintains activity against the most prevalent human STING variant (R232), effectively suppresses STING signaling in primary human CD14+ monocytes, and exhibits moderate metabolic stability. Collectively, these findings highlight <b>UM-203</b> as a promising scaffold for the development of therapeutics targeting STING-driven inflammatory and autoimmune diseases.